drugset / Trial / NCT04975724

Safety of Liposom With Citalopram in Elderly Patients With Major Depressive Disorder

NCT04975724

Phase 4 Unknown 150 enrolled Fidia Farmaceutici s.p.a.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if Liposom Forte will enhance the response to antidepressant therapy with citalopram in elderly patients suffering from Major Depressive Disorder (MDD).

Timeline

Start
2019-04-18
Primary completion
2025-10
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Liposom Forte Other / unclassified 28 mg Other
Background Citalopram Small molecule 10 mg